New mutations tied to rapidly progressing intrahepatic cholestasis
Researchers in China have identified five new mutations in the NR1H4 gene in three boys with progressive familial intrahepatic cholestasis type 5 (PFIC5) and…
News
GPR75 protein may be fatty liver disease therapeutic target: Study
Reduced activity of a protein called GPR75 appears to help prevent the buildup of fat in the liver and the subsequent development of metabolic dysfunction-associated…
Bylvay eases itch, signs of liver damage in Alagille, trial data show
Daily treatment with Bylvay (odevixibat) safely and effectively eases itching and lowers blood bile acid levels, a sign of liver damage, in children and adolescents…
Hepatitis Awareness Month promotes screening, vaccination
Throughout May, the U.S. Centers for Disease Control and Prevention (CDC) will work with public health partners to raise awareness of viral hepatitis…
New molecule to reduce liver scarring a potential PSC treatment
Researchers at the University of California San Diego (UCSD) have created a molecule, named antisense oligonucleotide (ASO) 56, that is able to potently reduce liver…
Low-dose soybean emulsion may avoid newborn cholestasis: Study
A reduced dose of soybean fat emulsion seems to be better than the standard dose at preventing parenteral nutrition-associated cholestasis in newborns undergoing surgery…
US government to launch 1st study of disease prevalence in MASLD
The U.S. government soon will launch a first national study to assess the prevalence of metabolic dysfunction-associated steatotic liver disease, or MASLD — a liver…
Triple blood test may be best at diagnosing biliary atresia
The blood levels of two proteins, called MMP-7 and SOX9, are significantly higher in infants with biliary atresia than in those with similar liver…
Gilead awards $4M funding to hepatitis B, C, D elimination projects
Gilead Sciences has awarded $4 million in funding via its ALL4LIVER grant program to organizations worldwide whose community-based efforts will help the World Health…
UDCA plus elafibranor best for treatment-resistant PBC: Analysis
Combining ursodeoxycholic acid (UDCA) with elafibranor, an experimental oral therapy for primary biliary cholangitis (PBC), may be the best treatment combination for lessening signs…
Recent Posts
- PBC treatment Ocaliva leaves U.S. market amid safety concerns
- When facing a hospital stay, pack a bag and hope for chocolate cake
- Hormone-like therapy NF-1 shows promise in ICP mouse study
- FDA weighs noninvasive biopsy alternative in MASH clinical trials
- Savoring the everyday moments that bring joy to our lives